Wed, Jul 23, 2014, 1:12 AM EDT - U.S. Markets open in 8 hrs 18 mins


% | $
Click the to save as a favorite.

Shire plc Message Board

  • shortningdough shortningdough Nov 6, 2007 11:54 PM Flag

    maybe it's good for adhd

    Shire says study did not meet primary endpoint

    By Angela Moore
    Last Update: 8:20 AM ET Nov 6, 2007Print Subscribe to RSS Disable Live Quotes

    NEW YORK (MarketWatch) - Shire Plc (SHPGY:SHPGY
    News, chart, profile, more

    Delayed quote dataAdd to portfolio
    Create alertInsider
    Sponsored by:
    SHPGY, , ) on Tuesday said a Phase II study of its drug Fosrenol drug did not meet its primary endpoint, to control serum phosphate within normal levels. The company said as a secondary endpoint, patients taking Fosrenol were found to have statistically significant reductions in serum phosphate levels after eight weeks of treatment compared with patients taking a placebo. Shares slipped 1% in premarket trading

253.96+1.16(+0.46%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.